MetLife Investment Management’s BioTelemetry, Inc. BEAT Stock Holding History

MetLife Investment Management’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-13,385	Closed	-$965K	–	2362
2020 Q4	$965K	Sell	13,385 -1,747	-12%	-$91.4K	0.01%	1153
2020 Q3	$690K	Hold	15,132	–	–	0.01%	1213
2020 Q2	$684K	Hold	15,132	–	–	0.01%	1208
2020 Q1	$583K	Hold	15,132	–	–	0.01%	1132
2019 Q4	$701K	Hold	15,132	–	–	0.01%	1275
2019 Q3	$616K	Hold	15,132	–	–	0.01%	1309
2019 Q2	$729K	Hold	15,132	–	–	0.01%	1271
2019 Q1	$948K	Hold	15,132	–	–	0.01%	1105
2018 Q4	$904K	Hold	15,132	–	–	0.01%	1058
2018 Q3	$975K	Hold	15,132	–	–	0.01%	1134
2018 Q2	$681K	Buy	+15,132	New	+$603K	0.01%	1216
2018 Q1	–	Sell	-13,262	Closed	-$397K	–	2269
2017 Q4	$397K	Buy	+13,262	New	+$384K	﹤0.01%	1536

Other funds holding BEAT

LCM

Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

MetLife Investment Management's BEAT Position: Q1 2021 in Review

MetLife Investment Management sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 13,385 shares — an estimated $965K sold.

MetLife Investment Management first reported a position in BEAT in Q4 2017 and held it in 12 quarters. The position peaked at $975K in Q3 2018. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

MetLife Investment Management reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
MetLife Investment Management sold 13,385 BioTelemetry, Inc. shares in Q1 2021, an estimated $965K.
MetLife Investment Management first reported a position in BioTelemetry, Inc. in Q4 2017 and held it in 12 quarters.
MetLife Investment Management's BioTelemetry, Inc. position peaked at $975K in Q3 2018.
1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on MetLife Investment Management's 13F filing for Q1 2021, filed 14 May 2021.